Acute Myeloid Leukemia Real World Treatment Patterns
NCT04230564 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2023-06-07
Summary
Among patients with a diagnosis of AML who received non-intensive chemotherapy:
* Describe patient demographic and clinical characteristics
* Describe treatment patterns
* Describe effectiveness outcomes
* Evaluate tumor response
Conditions
- Leukemia, Myeloid, Acute
Interventions
- DRUG
-
Patients taking azacitidine
- DRUG
-
patients taking venetoclax
- DRUG
-
glasdegib
patients taking glasdegib
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-10-31
- Primary Completion
- 2021-03-31
- Completion
- 2021-03-31
More Related Trials
-
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
NCT04062266 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
NCT04752163 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
NCT04912063 ·Status: TERMINATED ·Phase: PHASE1
-
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
NCT05431257 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
NCT06773208 ·Status: RECRUITING ·Phase: PHASE2
-
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
NCT04655391 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World
NCT04337138 ·Status: COMPLETED
-
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
NCT05554393 ·Status: RECRUITING ·Phase: PHASE2
-
Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia
NCT03573024 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
NCT04550442 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
NCT04128501 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
NCT02680951 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy
NCT04824924 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
NCT03699384 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML
NCT05053425 ·Status: UNKNOWN ·Phase: NA
-
Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML
NCT05654194 ·Status: UNKNOWN ·Phase: PHASE3
-
Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
NCT01743859 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
NCT05766514 ·Status: WITHDRAWN ·Phase: PHASE2
-
Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT02953561 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
NCT03151408 ·Status: TERMINATED ·Phase: PHASE3
-
Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia
NCT04867928 ·Status: UNKNOWN ·Phase: PHASE2
-
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
NCT03932318 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
NCT03586609 ·Status: RECRUITING ·Phase: PHASE2
-
Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
NCT04296214 ·Status: WITHDRAWN
-
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
NCT05209152 ·Status: TERMINATED ·Phase: PHASE1